AV-101, formerly known as 4-Chlorokynurenine; 4-Cl-KYN; AV-101; L-4-Cl-KYN; 4ClKYN; L-4ClKYN, is a NMDA glycine B receptor antagonist potentially for treatment of major depressive disorder. AV-101 is an orally bioavailable small molecule prodrug candidate that in vivo produces a glycine binding site NMDA receptor antagonist. AV-101 is in clinical development by VistaGen Therapeutics. Inc. as a potential new generation, fast-acting antidepressant, and for other central nervous system (CNS) indications. References: Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA Jr, Schwarcz R, Gould TD. The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. J Pharmacol Exp Ther. 2015 Oct;355(1):76-85. doi: 10.1124/jpet.115.225664. Epub 2015 Aug 11. PubMed PMID: 26265321; PubMed Central PMCID: PMC4576668.

纯度：≥98%

CAS：153152-32-0